On September 12, 2023, it was reported that investment management firm Beck Mack & Oliver LLC has reduced its stake in Waters Co. by 0.7% during the first quarter of the year. This information was disclosed in the company’s most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor now holds 227,731 shares of Waters’ stock after selling 1,567 shares during the mentioned period.
Waters is a reputable supplier of medical instruments, and this move by Beck Mack & Oliver LLC has affected their investment portfolio. Prior to this decrease in stake, Waters accounted for about 2.0% of Beck Mack & Oliver LLC’s portfolio, making it their 14th largest position. However, following the sale of shares, Waters now represents a slightly smaller percentage of their investment holdings.
The value of the liquidated portion of Beck Mack & Oliver LLC’s investment in Waters amounted to $70,512,000 as per the most recent SEC filing. Although this reduction may appear modest compared to their overall investment portfolio, it still signifies an adjustment made by the institutional investor.
In other news related to Waters, director Christopher A. Kuebler recently executed a share sale transaction on August 4th. The director sold 4,000 shares at an average price of $291.48 per share for a total transaction value of $1,165,920. Following this transaction, Kuebler now holds approximately 14,382 shares directly in the company which are valued around $4,192,065.36.
It is noteworthy that corporate insiders currently own approximately 0.98% of Waters’ stock based on available data from filings with the SEC. This piece of information indicates that insiders within the company hold a small portion of its outstanding shares.
These recent developments highlight changes within both institutional and insider ownership positions in Waters Co., providing investors and market observers with insights into the dynamics of the company’s stock holdings. It is important to note that these filings serve as a reference point for analyzing market trends and the behavior of key stakeholders.
Investors and analysts may find this information valuable as they continue to assess the performance and potential growth prospects of Waters Co., which operates in the medical instruments industry.
Aerovate Therapeutics, Inc.
AVTE
Neutral
Updated on: 05/12/2023
Financial Health
Weak
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Sell
Institutional Investors Adjust Positions in Waters as Research Analysts Provide Insights
Institutional investors, including Itau Unibanco Holding S.A., ETF Managers Group LLC, Whittier Trust Co., Czech National Bank, and CWM LLC, have made notable changes to their positions in Waters (NYSE:WAT). Itau Unibanco raised its position by 22.3% during the fourth quarter, now owning 181 shares worth $62,000. ETF Managers Group LLC increased its position by 1.5% during the first quarter, now owning 2,324 shares worth $720,000. Whittier Trust Co. raised its position by 7.9% during the same period and now owns 520 shares worth $161,000. Czech National Bank also raised its position by 0.6%, now holding 6,995 shares worth $2,166,000. Meanwhile, CWM LLC increased its position by 12.4%, now owning 372 shares worth $115,000.
These institutional investors collectively own approximately 94.01% of Waters stock.
Several research analysts have also provided their insights on Waters. StockNews.com gave the company a “hold” rating in a report released on August 17th. Barclays also increased their price target from $275 to $288 and assigned an “equal weight” rating to the stock on August 3rd.
According to Bloomberg.com’s analysis of various ratings and reports, Waters currently has a consensus rating of “Hold” from seven analysts with an average price target of $319.13.
On Tuesday’s trading session, WAT stock opened at $263.30 per share. The company maintains a quick ratio of 1.41 and a current ratio of 2.08 while having a debt-to-equity ratio of 3.35.
Waters boasts a market capitalization of approximately $15.56 billion with a price-to-earnings ratio of 23.22 and a P/E/G ratio of 3.29, indicating potential company growth.
The stock has had a 50-day moving average price of $277.88 and a two-hundred-day moving average price of $283.40. Over the past twelve months, Waters experienced volatility, ranging from $248.18 as its lowest trading price to $353.70 as its highest.
In terms of sales performance, Waters announced its quarterly earnings results on August 2nd, revealing an earnings per share of $2.80 for the quarter. The figure surpassed analysts’ consensus estimates by $0.21.
Furthermore, during the same period, the company reported revenue amounting to $740.58 million compared to the consensus estimate of $733.51 million.
Waters’ robust financial performance is evident in its return on equity of 124.03% and a net profit margin of 22.54%.
Looking ahead, analysts anticipate that Waters will post approximately $12.24 earnings per share for the current fiscal year.
In conclusion, with institutional investors making adjustments to their positions in Waters and research analysts providing their rating and analysis on the stock’s performance, it is clear that this medical instruments supplier is under scrutiny within the investment community.
Discussion about this post